Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study

Yolanda Meije, Carles Pigrau, Núria Fernández-Hidalgo, Mercedes Clemente, Lucía Ortega, Xavier Sanz, Jose Loureiro-Amigo, Montserrat Sierra, Ana Ayestarán, Alejandra Morales-Cartagena, Alba Ribera, Alejandra Duarte, Gabriela Abelenda, Jesús Rodríguez-Baño, Joaquim Martínez-Montauti

    Research output: Contribution to journalArticleResearch

    3 Citations (Scopus)

    Abstract

    © 2019 Elsevier B.V. and International Society of Chemotherapy Carbapenems are considered the treatment of choice for extended-spectrum β-lactamase (ESBL)- or AmpC β-lactamase-producing Enterobacteriaceae bacteraemia. Data on the effectiveness of non-intravenous carbapenem-sparing antibiotic options are limited. This study compared the 30-day mortality and clinical failure associated with the use of carbapenems versus alternative non-intravenous antibiotics for the definitive treatment of ESBL/AmpC-positive Enterobacteriaceae bacteraemia. This 12-year retrospective study (2004–2015) included all patients with bacteraemia due to ESBL/AmpC-producing Enterobacteriaceae at a Spanish hospital. Given the lack of randomisation of initial therapies, a propensity score for receiving carbapenems was calculated. There were 1115 patients with a first episode of bacteraemia due to Escherichia coli or Klebsiella pneumoniae, of which 123 (11.0%) were ESBL/AmpC-positive. There were 101 eligible patients: 59 in the carbapenem group and 42 in the alternative treatment group (trimethoprim/sulfamethoxazole 59.5%, quinolones 21.4%). The most frequent sources of infection were urinary (63%) and biliary (15%). Compared with the carbapenem group, patients treated with an alternative regimen had a shorter hospital stay [median (IQR) 7 (5–10) days vs. 12 (9–18) days; P < 0.001]. Use of an alternative non-intravenous therapy did not increase mortality (OR = 0.27, 95% CI 0.05–1.61; P = 0.15). After controlling for confounding factors with the propensity score, the adjusted OR of carbapenem treatment was 4.95 (95% CI 0.94–26.01; P = 0.059). Alternative non-intravenous carbapenem-sparing antibiotics could have a role in the definitive treatment of ESBL/AmpC-positive Enterobacteriaceae bacteraemia, allowing a reduction in carbapenem use. Use of trimethoprim/sulfamethoxazole in this series showed favourable results.
    Original languageEnglish
    Pages (from-to)189-196
    JournalInternational Journal of Antimicrobial Agents
    Volume54
    DOIs
    Publication statusPublished - 1 Aug 2019

    Keywords

    • AmpC β-lactamase
    • Carbapenem-sparing antibiotics
    • Enterobacteriaceae bacteraemia
    • Extended-spectrum β-lactamase
    • Stewardship
    • Trimethoprim/sulfamethoxazole

    Fingerprint Dive into the research topics of 'Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study'. Together they form a unique fingerprint.

  • Cite this

    Meije, Y., Pigrau, C., Fernández-Hidalgo, N., Clemente, M., Ortega, L., Sanz, X., Loureiro-Amigo, J., Sierra, M., Ayestarán, A., Morales-Cartagena, A., Ribera, A., Duarte, A., Abelenda, G., Rodríguez-Baño, J., & Martínez-Montauti, J. (2019). Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study. International Journal of Antimicrobial Agents, 54, 189-196. https://doi.org/10.1016/j.ijantimicag.2019.05.004